INS and Hypoglycemia: The creation of a desirable therapeutic basal insulin needs to address, at least, 3primary challenges: (a) duration of action, (b) day-to-day and/or within-day SCabsorption variability, and (c) hypoglycemia risk, especially during the overnighthours.